This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
by Zacks Equity Research
Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Boston Scientific (BSX) Grows IC Business With New FDA Nod
by Zacks Equity Research
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
ICON (ICLR) Gains From Strategic Deals, New Innovations
by Zacks Equity Research
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
by Zacks Equity Research
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
GE HealthCare's (GEHC) New Launch to Enhance Precision Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.
Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300
by Zacks Equity Research
Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.
Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition
by Zacks Equity Research
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
by Zacks Equity Research
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
5 Best PEG-Based GARP Stocks for Investors
by Urmimala Biswas
Here are the five stocks that qualify our screening criteria ¿¿¿ RCL, DVA, F, FIS and ITRI.
Waters (WAT) Boosts LC Solutions Portfolio With New Software
by Zacks Equity Research
Waters (WAT) unveils HPLC CONNECT software, bolstering its liquid chromatography solutions portfolio.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
by Zacks Equity Research
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
Charles River (CRL) Forges Collaboration With Wheeler Bio
by Zacks Equity Research
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.